The AMPK protection against the deleterious effect of lipotoxicity on lysosomes is also in line with our previous study showing that AICAR administration is associated with reduced lysosomal enlargement in proximal tubules of mice with obesity-induced CKD [13]. Here, PRKAA2 is linked to chronic kidney disease.